In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $65.00. The company’s shares closed last Friday at $45.36.
According to TipRanks, Olson is a 5-star analyst with an average return of 16.1% and a 45.08% success rate. Olson covers the Healthcare sector, focusing on stocks such as Biogen, Neurocrine, and Viking Therapeutics.
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $59.00, a 30.07% upside from current levels. In a report released on February 22, Piper Sandler also maintained a Buy rating on the stock with a $63.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $324.51 million and a GAAP net loss of $9.26 million. In comparison, last year the company earned a revenue of $151.89 million and had a GAAP net loss of $52.43 million
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year. Last month, Eugene Schneider, the EVP, Chf Clinical Develop Ofcr of IONS sold 8,000.00 shares for a total of $427,920.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ionis Pharmaceuticals (IONS) Company Description:
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $63 from $62 at Piper Sandler
- Ionis reports fourth quarter and full year 2023 financial results
- Ionis Pharmaceuticals sees FY24 revenue over $575M, consensus $636.36M
- Ionis Pharmaceuticals reports Q4 EPS (6c), consensus (83c)
- IONS Upcoming Earnings Report: What to Expect?
